Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-18.80%
↓ 136% below average
Average (5y)
52.72%
Historical baseline
Range
High:112.19%
Low:-18.80%
Volatility
248.5%
High variability
| Period | Value |
|---|---|
| 2024 | -18.80% |
| 2023 | 37.17% |
| 2022 | 112.19% |
| 2021 | 79.07% |
| 2020 | 106.69% |
| 2019 | 0.00% |